L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats

Levodopa (L-DOPA) is still the most effective drug for the treatment of Parkinson’s disease (PD). However, the long-term therapy often triggers L-DOPA-induced dyskinesia (LID). Metabotropic glutamate receptor type 5 (mGluR5) is abundant in the basal ganglia, and its inhibition is thought to modulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yixian, Shu, Haiyang, Li, Li, Zhen, Tili, Zhao, Junyan, Zhou, Xianju, Luo, Weifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238196/
https://www.ncbi.nlm.nih.gov/pubmed/30439288
http://dx.doi.org/10.1177/1759091418811021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238196/
https://www.ncbi.nlm.nih.gov/pubmed/30439288
http://dx.doi.org/10.1177/1759091418811021

Ejemplares similares